Compare
Tenaya Therapeutics, Inc. vs Inhibrx Biosciences, Inc. vs ImageneBio, Inc. vs Precision Biosciences Inc
| Latest fiscal year | Tenaya Therapeutics, Inc. TNYA | Inhibrx Biosciences, Inc. INBX | ImageneBio, Inc. IMA | Precision Biosciences Inc DTIL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $1.30M | $800.0K | $34.26M |
| Revenue growth (YoY) | n/a | +550.0% | -77.1% | -50.1% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | n/m | -152.2% |
| Net margin | n/a | n/m | n/m | -133.4% |
| Net income | -$90.60M | -$140.06M | -$45.35M | -$45.72M |
| EPS (Diluted) | -$0.59 | -$9.04 | -$9.64 | -$3.56 |
| Operating cash flow | -$68.26M | -$129.79M | -$47.84M | -$65.84M |
| Free cash flow | -$68.88M | -$129.82M | n/a | -$65.93M |
| Cash & equivalents | $100.55M | $124.22M | $94.53M | $110.82M |
| Total assets | $146.92M | $146.48M | $152.98M | $154.42M |
| Total liabilities | $23.66M | $138.49M | $19.84M | $62.17M |
| Shareholders' equity | $123.27M | $7.99M | $133.14M | $92.25M |
| Return on year-end equity | -73.5% | n/m | -34.1% | -49.6% |
| Shares outstanding | 216.76M | 14.58M | n/a | 24.09M |
Revenue, most recent five fiscal years
| Fiscal year | Tenaya Therapeutics, Inc. | Inhibrx Biosciences, Inc. | ImageneBio, Inc. | Precision Biosciences Inc |
|---|---|---|---|---|
| Latest | n/a | $1.30M Ended 2025-12-31 | $800.0K Ended 2025-12-31 | $34.26M Ended 2025-12-31 |
| 1 year earlier | n/a | $200.0K Ended 2024-12-31 | $3.50M Ended 2024-12-31 | $68.70M Ended 2024-12-31 |
| 2 years earlier | n/a | $1.80M Ended 2023-12-31 | $9.16M Ended 2023-12-31 | $48.73M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $15.62M Ended 2022-12-31 | $25.10M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $30.98M Ended 2021-12-31 | $115.53M Ended 2021-12-31 |